Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nivolumab Following Haploidentical BMT in Sarcomas
NCT03465592Phase 2Recruiting
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center
- Start
- May 2018
- Primary completion
- Jan 2027
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of nivolumab in sarcoma, solid tumor, sponsored by Sidney Kimmel Comprehensive Cancer Center. Started May 2018; status: recruiting.
02
Drugs
03
Conditions
sarcomasolid tumor
Beyond the preview
Go deeper on NCT03465592.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03465592.